Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NETs and endocrine tumours

1914MO - Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912

Date

18 Sep 2020

Session

Mini Oral - NETs and endocrine tumours

Topics

Cancer Treatment in Patients with Comorbidities

Tumour Site

Thyroid Cancer

Presenters

Eric Sherman

Citation

Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293

Authors

E.J. Sherman1, J. Harris2, K.C. Bible3, P. Xia4, R.A. Ghossein5, C.H. Chung6, N. Riaz7, B. Gunn8, R.L. Foote9, S. Yom10, S.J. Wong11, S. Koyfman4, M.F. Dzeda12, D.A. Clump13, S. Khan14, A. Chakravarti15, K. Redmond16, P. Torres-Saavedra2, Q. Le17, N. Lee18

Author affiliations

  • 1 Medicine, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Statistics And Data Management Center, NRG Oncology, 19103 - Philadelphia/US
  • 3 Medicine, Mayo Clinic, 55905 - Rochester/US
  • 4 Radiation Oncology, Cleveland Clinic Foundation, 44195 - Cleveland/US
  • 5 Pathology, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 6 Head & Neck- Endocrine Oncology Department, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 7 Radiation Oncology, Memorial Sloan Kettering 60th Street Outpatient Center, 10022 - New York/US
  • 8 Radiation Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 9 Radiation Oncology, Mayo Clinic, 55905 - Rochester/US
  • 10 Radiation Oncology, UCSF-Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 11 Medicine, Medical College of Wisconsin, 53226 - Milwaukee/US
  • 12 Radiation Oncology, ChristianaCare Health System, Inc.-Helen F. Graham Cancer Center & Research Institute, 19713 - Newark/US
  • 13 Department Of Radiation Oncology, UPMC Shadyside, PA 15232 - Pittsburgh/US
  • 14 Medicine, UT Southwestern/Simmons CC-Dallas, 75390 - Dallas/US
  • 15 Department Of Radiation Oncology, Ohio State University Comprehensive Cancer Center, 43210 - Columbus/US
  • 16 Department Of Radiation Oncology, University of Cincinnati/Barrett Cancer Center, 45267 - Cincinnati/US
  • 17 Department Of Radiation Oncology, Stanford Cancer Institute Palo Alto, 94305 - Stanford/US
  • 18 Radiation Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1914MO

Background

Anaplastic thyroid cancer (ATC) is a rare/aggressive cancer with no standard radiation-based local treatment. Achieving locoregional disease control in the neck is critical due to major concerns of airway and esophageal compromise. Based on data suggesting synergy between pazopanib (P) and paclitaxel (T) in ATC, NRG Oncology conducted a randomized phase II study comparing concurrent T and intensity modulated radiation therapy (IMRT) with either P or placebo (C).

Methods

The study arm evaluated 2-3 weeks of weekly T (80 mg/m2) and daily P suspension (PS) 400 mg followed by concurrent weekly T (50 mg/m2), daily PS (300 mg), and IMRT 66 Gy. The standard arm substituted C for PS. Inclusion criteria included pathologic diagnosis of M0/M1 ATC (central path review), Zubrod 0-2, no recent hemoptysis/bleeding, no brain metastases. Target accrual was 88 patients (pts) (79 eligible) to show a >37.5% reduction in the hazard rate for overall survival (OS) with addition of PS (1-sided alpha 0.15, beta 0.2). Final analysis, after accounting for 1 interim analysis, was 1-sided log-rank test at 0.1379 level in eligible pts.

Results

89 pts (71 eligible) were accrued from 6/23/14-12/30/16, completing accrual 14 months earlier than projected. Pts excluded per protocol in each arm - PS 6; C 12. Median age 65 years. Female 52.1%. Zubrod 0-1 91.5%. Total thyroidectomy 36.6%; partial thyroidectomy 21.1%. M0 disease 56.3%. OS was not significantly higher with PS compared to C (p=0.28); hazard ratio (PS/C) was 0.86 (95% CI 0.52 - 1.43). OS and adverse events (AE) rates are in the table. Table: 1914MO

Pazopanib (n=36) Placebo (n=35)
OS rate (95% CI)
1-year 37.1% (21.1-53.2%) 29.0% (13.2-44.8%)
2-year 20.0% (6.7-33.3%) 12.9% (1.1-24.6%)
3-year 17.1% (4.7-29.6%) 9.7% (0-20.0%)
Highest treatment-related AE (n=36) (n=34)
Grade 3 52.8% 55.9%
Grade 4 33.3% 26.5%
Grade 5 2.8% (1 pt) 2.9% (1 pt)

Conclusions

NRG-RTOG 0912 is the largest randomized ATC study that completed accrual demonstrating feasibility in the cooperative group setting. Although a statistically significant improvement in OS was not seen with PS added to T and IMRT, the OS rates and feasibility data from this prospective clinical trial will be useful to help design future studies in this rare and aggressive disease.

Clinical trial identification

RTOG 0912.

Editorial acknowledgement

Legal entity responsible for the study

NRG/RTOG Oncology.

Funding

This project was supported by grants UG1CA189867 (NRG Oncology NCORP), U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), & U24CA180803 (IROC) from the National Cancer Institute (NCI) and Novartis.

Disclosure

E.J. Sherman: Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Regeneron; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly/Loxo; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Plexxicon. P. Xia: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Philips Healthcare; Research grant/Funding (institution): Advanced Oncotherapy. C.H. Chung: Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy: CUE Biopharma; Advisory/Consultancy, Research grant/Funding (institution): Ignyta; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Mirati Therapeutics; Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (institution): IRX Therapeutics; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Lion Biotechnologies; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Regeneron. R.L. Foote: Licensing/Royalties: Bionix; Travel/Accommodation/Expenses: Hitachi Chemical. S. Yom: Research grant/Funding (institution): BioMimetix; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Merck. S.J. Wong: Research grant/Funding (institution): Merck; Research grant/Funding (institution): Novartis. S. Koyfman: Research grant/Funding (institution): Merck Sharp & Dohme. S. Khan: Honoraria (institution), Advisory/Consultancy: Ariad; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Genentech/Roche; Honoraria (self), Speaker Bureau/Expert testimony: Genzyme; Advisory/Consultancy, Research grant/Funding (institution): Bayer/Onyx; Advisory/Consultancy: Foundation Medicine; Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Celldex; Research grant/Funding (institution): Formation Biologics; Research grant/Funding (institution): Gilead Sciences; Research grant/Funding (institution): Loxo; Research grant/Funding (institution): Merck; Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Threshold Pharmaceuticals. Q-T. Le: Advisory/Consultancy: Merck; Shareholder/Stockholder/Stock options: Aldea; Travel/Accommodation/Expenses: Genentech; Advisory/Consultancy: Grail. N. Lee: Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Merck; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Vertex. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.